Melanoma oncology. Study hereditary genetics and irAE. LA explant in SF via OH. Sports fan, geek, and mom. COI https://xitter.cf/t.co/UJ7zV93Ett 🦋@funchainmd.bsky.social
Stanford, CA
Joined August 2016
- Tweets8.2K
- Following1.3K
- Followers2.6K
- Likes19.4K
Pinned Tweet
My dream is to love what I do so much that I have trouble leaving it 67 years later #ThankYouVin 💙 xitter.cf/dodgers/status/7826543…
Pauline Funchain retweeted
I admit i am very much into intismeran…and it seems many others too as it is standing room only here…
Fabulous presentation/data on the Interpath-001 trial demonstrating clear benefit of this space age bespoke neoantigen vaccine along w pembro for pts w resected high risk melanoma as to 40% or so improvement in RFS/distant met free survival
Indeed a landmark trial for precision medicine and hopefully not too Long before we see confirmation in nsclc/other trials!
Interpath- indeed makes us foresee a wonderful path and light ahead for our field!
#ESMO26
Pauline Funchain retweeted
Landmark moment in personalized inmunoTx for cancer: individualized mRNA-based vaccine added to pembro prolonged RFS vs pembro alone in resected melanoma: standing ovation @myESMO #ESMO26 #ESMOAmbassadors @ProfGLongMIA gave a fantastic presentation! @EvanHallMD @FunchainMD
A long-awaited breakthrough in cancer vaccines.
One patient. One tumor. One personalized mRNA vaccine.
INTErpath-001 brings this vision closer to clinical reality. Are we ready to deliver it?
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @ProfGLongMIA @FAndreMD @curijoey @YJanjigianMD
Pauline Funchain retweeted
👑 Presidential #ESMO26! INTerpath-001: personalized mRNA vaccination reaches phase III in melanoma.
Resected stage IIB–IV melanoma, N=1,137: intismeran + pembrolizumab vs pembrolizumab.
💥 At 24 months:
• RFS: 82.2% vs 70.0% → HR 0.58
• DMFS: 88.5% vs 80.2% → HR 0.62
• Absolute gains: +12.2% RFS / +8.3% DMFS
• Benefit emerges mainly after 6 months
• Grade ≥3 AEs: 23.6% vs 20.3%
• OS still immature
A clinically meaningful new mechanism, but the real question now is positioning 🤔
For macroscopic stage III: adjuvant personalized vaccine after surgery, or neoadjuvant ipi/nivo before it? Biomarkers may ultimately decide.
Congrats to @ProfGLongMIA and all the team! 👏🏼
@OncoAlert
@OncoReporte @myESMO @_SEOM @GrupoMelanoma
Pauline Funchain retweeted
Our #JACCCardioonc review led by @uclaimchiefs @Tylermorad & IM res @MKeykhaeiMD & @A_SteinMerlob tackles the lesser-explored aspects of ICI myocarditis care--the outpatient care, or the aftermath.
🙏 @JACCJournals for the opportunity
#bruinhearts
shorturl.at/PMlfR
🧵1/
🏔️Profound! Ellen Langer - @ellenjl, the first woman tenured @PsychHarvard, asks us to be open to what and who are around us and what they are presenting to us, what might be new (rather than defaulting to what we think about them a priori)
Incredible @StanfordMed Grand Rounds
🌪️ Whirlwind activity @ASCO Leadership Development Program! Three days of intense reflection, conflict management, quality improvement, project development 📈
@thenasheffect @ChristineBestv1 @VaiaFlorou @gandhi_shipra @koshkin85 @Sarbaji85064063 @joshuamammen @Dr_JeannyAC ++
Pauline Funchain retweeted
@ASCO LDP group dinner after a fun day of work with this fantastic group ..@ChristineBestv1 @FunchainMD @VaiaFlorou @gandhi_shipra @koshkin85 @Sarbaji85064063 and many others.
Pauline Funchain retweeted
Important study by @ldiaz1971 @MSKCancerCenter advocating for universal germline testing after a cancer diagnosis. Among ~40,000 patients, 18.4% of early-onset, 15.6% of average-onset, & 12.3% of late-onset cancers harbor pathogenic germline alterations.
aacrjournals.org/cancerdisco…
Pauline Funchain retweeted
SAFE-HEART, SCHOLAR, & 5FU studies have shown strategies of PC are possible. But the 🌊 of cancer tx ,esp w/ immunotherapy, provide a neverending challenge to #cardioonc in how to give cancer pts the best chance possible. We hope this review generates debate & discussion! Fin/
Pauline Funchain retweeted
Now online in @CD_AACR: Universal Germline Genetic Testing after a Diagnosis of Cancer - by @StadlerZsofia, @ldiaz1971, and colleagues @MSKCancerCenter
Now online: Universal Germline Genetic Testing after a Diagnosis of Cancer doi.org/10.1158/2159-8290.CD…
Movin’ on up! ⬆️ Dynamic growth of @StanfordCancer in just one year 🗓️ (here the medical oncology slide with new faculty) and the achievements that can be unlocked with intentional growth and the right people in key areas of oncology #MelanomaStrong #WeAreStanford
Good morning Asilomar 🌞 Every place has traditions, and this @StanfordCancer tradition showcases all the Stanfordisms - truly a community based in the exchange of science, medicine in a beautiful locale. Literally hearing science to the backdrop of seagulls and crashing waves 🌊
Ride like the wind Cleveland! 🚴 @bikeVeloSano 🥰
It is a beautiful evening in Cleveland @bikeVeloSano @ClevelandClinic Thank you for the community coming together to support #CancerResearch @ClevelandClinic !
Pauline Funchain retweeted
Had the chance to sit down with @wolchokj, a pioneering investigator in #melanoma. A marvelous opportunity to discuss an evolution from dismal days when chemotherapy was the prevailing option to the tidal wave of novel CPIs, TILs & most recently #personalized #vaccines that are transforming outcomes. An episode you will not want to miss!
@FunchainMD @DrBetofMDPhD @OmidHamidMD @kmargolin @RichardWJoseph @VivekSubbiah @neerajaiims @ASCO
🎙 @montypal of @cityofhope and pioneering investigator Dr. Jedd Wolchok of @WeillCornell discuss the remarkable evolution in melanoma treatments on the latest episode of the #ASCODailyNews Podcast: bit.ly/3SzPqnW
On uveal melanoma: normally I limit conference posts that are only people, no data, but what yesterday’s @CureMelanoma agenda was exactly that: people. Here: the passionate, the survivors, the surviving, and seekers. For #RareCancer, we move progress person by person 👁️🖤🪜
Pauline Funchain retweeted
Join us Oct. 10 for an interactive CME workshop designed for healthcare providers focused on advancing health equity in skin cancer care. Healthcare providers will gain actionable strategies to identify and address barriers to equitable care, define ideal care environments, and use shared decision-making to help optimize clinical outcomes. Connect with colleagues and experts to strengthen your approach to providing equitable dermatologic care in your community.
CME credit is available. Scroll down the page to register for the conference first and add this workshop to your calendar: buff.ly/mQxjnEX @Medscape Education
#SkinCancer #Melanoma #healthequity
Pauline Funchain retweeted
Wow!! Powerful talks and even more powerful stories from these incredible superwomen leaders! 💪👏 #LEAD2026
A few pearls:
- Say yes even before you feel ready
- Leap and the net will appear
- Take care of your work family
- Learn through people
- Get intentionally uncomfortable
🙏 #TriciaKalwar @ndenduluri1 #JodiBrass @lynn_schuchter @AnaVManana @rachnatshroff @KatieLaiMD_MPH #MedEd #Womeninmedicine #womeninoncology #oncology #hematology @BioAscend
Pauline Funchain retweeted
Phenomenal & fun melanoma session with @DrSapnaPatel @DanielOlsonMD Dr. Hallmeyer #BGT2026 @chadinabhan
@VivekSubbiah @IshwariaMD @BalazsHalmosMD @Dr_R_Kurzrock @ErikaHamilton9 @BlasePolite @GIcancerDoc @CathyEngMD @EvanHallMD @FunchainMD @karima_oualla @OncBrothers @OncoAlert
Parting thoughts on closing the @StanfordCancer Comprehensive Cancer Research Training Program #CCRTP26
Thanks to Charlette and Rachel for their capable and joyful administration 👏
Loved meeting people from all avenues of cancer research and from all regions (and states)! ♥️
If your very excellent oncology line up ends with GU oncology can you say the science was good to the last drop? 🤔Kris Prado, Alice Fan, @geoffsonn finished strong @StanfordCancer #CCRTP26
Thank you to everyone who attended these 2 fabulous days of science! #LearnOn
